CliffBio
small molecule

CLINDAMYCIN PHOSPHATE

CLINDAMYCIN PHOSPHATE

Loss of exclusivity—loss of exclusivity
CompanyTaro Pharmaceutical Industries →See this company's full patent-cliff portfolio

Drug detail

Brand nameCLINDAMYCIN PHOSPHATE
Active ingredientCLINDAMYCIN PHOSPHATE
Strength1%
Dosage formAEROSOL, FOAM
RouteTOPICAL
ModalitySmall molecule
FDA approvalMarch 2020
Marketing statusRX

More from Taro Pharmaceutical Industries

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

CLINDAMYCIN PHOSPHATE patent cliff — loss of exclusivity — | CliffBio